Skip to main content
European Commission logo
Deutsch Deutsch
CORDIS - Forschungsergebnisse der EU
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Inhalt archiviert am 2024-05-27

European vaccine effort against hiv/aids - ii

Ziel

HIV-1 and AIDS are spreading in Africa and Asia at unprecedented speed. A vaccine against HIV-1/AIDS is urgently needed. Vaccine candidates that show most promise in simian AIDS models are based on a prime-boost strategy, applying naked DNA or alphaviruses as prime and pox viruses as boost. The objectives of the EuroVac- II project are to demonstrate in a phase I trial of humans: firstly the ability of Semliki Forest virus (SFV) to prime anti-HIV immune responses, - compared to the attenuated poxvirus NYVAC -, using a recombinant gp140 protein boost; and secondly the ability of SFV priming, - using DNA priming as benchmark -, to improve the immune responses elicited by NYVAC + rgp140 vaccination. This design will provide conclusions concerning the relative immunogenicity of different prime-boost strategies. The HIV-1 genes used are recovered from a primary isolate belonging to HIV-1 subtype C, the most frequent cause of AIDS worldwide. The choice of genes (gag, pol, nef) other than envelope is based on the frequency of HIV-specific T-cell responses in long-term asymptomatic HIV infected individuals.

Wissenschaftliches Gebiet

CORDIS klassifiziert Projekte mit EuroSciVoc, einer mehrsprachigen Taxonomie der Wissenschaftsbereiche, durch einen halbautomatischen Prozess, der auf Verfahren der Verarbeitung natürlicher Sprache beruht.

Aufforderung zur Vorschlagseinreichung

Data not available

Koordinator

KAROLINSKA INSTITUTE
EU-Beitrag
Keine Daten
Adresse
13,Nobels väg 16
171 77 Stockholm
Schweden

Auf der Karte ansehen

Gesamtkosten
Keine Daten

Beteiligte (12)